These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 17199880)

  • 1. An overview of regular dialysis treatment in Japan (as of 31 December 2004).
    Nakai S; Wada A; Kitaoka T; Shinzato T; Nagura Y; Kikuchi K; Masakane I; Shinoda T; Yamazaki C; Sakai R; Marubayashi S; Morita O; Iseki K; Usami T; Kimata N; Suzuki K; Tabei K; Fushimi K; Miwa N; Yauchi M; Wakai K; Akiba T
    Ther Apher Dial; 2006 Dec; 10(6):476-97. PubMed ID: 17199880
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The current state of chronic dialysis treatment in Japan (as of December 31, 2000).
    Ther Apher Dial; 2003 Feb; 7(1):3-35. PubMed ID: 12921111
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overview of regular dialysis treatment in Japan (as of 31 December 2009).
    Nakai S; Iseki K; Itami N; Ogata S; Kazama JJ; Kimata N; Shigematsu T; Shinoda T; Shoji T; Suzuki K; Taniguchi M; Tsuchida K; Nakamoto H; Nishi H; Hashimoto S; Hasegawa T; Hanafusa N; Hamano T; Fujii N; Masakane I; Marubayashi S; Morita O; Yamagata K; Wakai K; Wada A; Watanabe Y; Tsubakihara Y
    Ther Apher Dial; 2012 Feb; 16(1):11-53. PubMed ID: 22248195
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An overview of regular dialysis treatment in Japan as of 31 December 2003.
    Patient Registration Committee, Japanese Society for Dialysis Therapy, Tokyo, Japan
    Ther Apher Dial; 2005 Dec; 9(6):431-58. PubMed ID: 16354276
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overview of regular dialysis treatment in Japan (as of 31 December 2008).
    Nakai S; Suzuki K; Masakane I; Wada A; Itami N; Ogata S; Kimata N; Shigematsu T; Shinoda T; Syouji T; Taniguchi M; Tsuchida K; Nakamoto H; Nishi S; Nishi H; Hashimoto S; Hasegawa T; Hanafusa N; Hamano T; Fujii N; Marubayashi S; Morita O; Yamagata K; Wakai K; Watanabe Y; Iseki K; Tsubakihara Y
    Ther Apher Dial; 2010 Dec; 14(6):505-40. PubMed ID: 21118359
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overview of regular dialysis treatment in Japan as of 31 December 2006.
    Nakai S; Masakane I; Akiba T; Shigematsu T; Yamagata K; Watanabe Y; Iseki K; Itami N; Shinoda T; Morozumi K; Shoji T; Marubayashi S; Morita O; Kimata N; Shoji T; Suzuki K; Tsuchida K; Nakamoto H; Hamano T; Yamashita A; Wakai K; Wada A; Tsubakihara Y
    Ther Apher Dial; 2008 Dec; 12(6):428-56. PubMed ID: 19140842
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overview of regular dialysis treatment in Japan (as of 31 December 2005).
    Nakai S; Masakane I; Akiba T; Iseki K; Watanabe Y; Itami N; Kimata N; Shigematsu T; Shinoda T; Syoji T; Syoji T; Suzuki K; Tsuchida K; Nakamoto H; Hamano T; Marubayashi S; Morita O; Morozumi K; Yamagata K; Yamashita A; Wakai K; Wada A; Tsubakihara Y
    Ther Apher Dial; 2007 Dec; 11(6):411-41. PubMed ID: 18028170
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An overview of regular dialysis treatment in Japan (as of 31 December 2007).
    Nakai S; Masakane I; Shigematsu T; Hamano T; Yamagata K; Watanabe Y; Itami N; Ogata S; Kimata N; Shinoda T; Syouji T; Suzuki K; Taniguchi M; Tsuchida K; Nakamoto H; Nishi S; Nishi H; Hashimoto S; Hasegawa T; Hanafusa N; Fujii N; Marubayashi S; Morita O; Wakai K; Wada A; Iseki K; Tsubakihara Y
    Ther Apher Dial; 2009 Dec; 13(6):457-504. PubMed ID: 19954472
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An overview of regular dialysis treatment in Japan (as of 31 December 2002).
    Patient Registration Committee, Japanese Society for Dialysis Therapy
    Ther Apher Dial; 2004 Oct; 8(5):358-82. PubMed ID: 15663532
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Attainment of the Japanese Society for Dialysis Therapy guidelines for the management of secondary hyperparathyroidism in chronic hemodialysis patients in our clinic.
    Sato Y; Eriguchi R; Umakoshi J; Kato M
    Ther Apher Dial; 2007 Oct; 11 Suppl 1():S48-53. PubMed ID: 17976086
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The 1998 report of the Japanese National Registry data on pediatric end-stage renal disease patients.
    Hattori S; Yosioka K; Honda M; Ito H;
    Pediatr Nephrol; 2002 Jun; 17(6):456-61. PubMed ID: 12107812
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An overview of regular dialysis treatment in Japan (as of 31 December 2010).
    Nakai S; Iseki K; Itami N; Ogata S; Kazama JJ; Kimata N; Shigematsu T; Shinoda T; Shoji T; Suzuki K; Taniguchi M; Tsuchida K; Nakamoto H; Nishi H; Hashimoto S; Hasegawa T; Hanafusa N; Hamano T; Fujii N; Masakane I; Marubayashi S; Morita O; Yamagata K; Wakai K; Wada A; Watanabe Y; Tsubakihara Y
    Ther Apher Dial; 2012 Dec; 16(6):483-521. PubMed ID: 23190510
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of calcium, phosphorus and bone metabolism in dialysis patients using sevelamer hydrochloride and vitamin D therapy.
    Ishida M; Yao N; Yachiku S; Anzai T; Kobayashi T; Ishida H
    Ther Apher Dial; 2005 Aug; 9 Suppl 1():S16-21. PubMed ID: 16109136
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vitamin D deficiency and associated factors in hemodialysis patients.
    Jean G; Charra B; Chazot C
    J Ren Nutr; 2008 Sep; 18(5):395-9. PubMed ID: 18721733
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overview of regular dialysis treatment in Japan (as of 31 December 2011).
    Nakai S; Watanabe Y; Masakane I; Wada A; Shoji T; Hasegawa T; Nakamoto H; Yamagata K; Kazama JJ; Fujii N; Itami N; Shinoda T; Shigematsu T; Marubayashi S; Morita O; Hashimoto S; Suzuki K; Kimata N; Hanafusa N; Wakai K; Hamano T; Ogata S; Tsuchida K; Taniguchi M; Nishi H; Iseki K; Tsubakihara Y
    Ther Apher Dial; 2013 Dec; 17(6):567-611. PubMed ID: 24330555
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Renal Epidemiology and Information Network: 2007 annual report ].
    Couchoud C; Lassalle M; Stengel B; Jacquelinet C
    Nephrol Ther; 2009 Jun; 5 Suppl 1():S3-144. PubMed ID: 19524212
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of sevelamer on mineral metabolism and hyperparathyroidism in Japanese hemodialysis patients.
    Inoue T; Nagatoya K; Kagitani M; Shibahara N; Ueda H; Katsuoka Y; Ohashi S; Kitagawa Y; Nishimoto K; Yasuda H;
    Ther Apher Dial; 2007 Jun; 11(3):210-4. PubMed ID: 17498003
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of monthly dose and regular dosing of intravenous active vitamin D use on mortality among patients undergoing hemodialysis.
    St Peter WL; Li S; Liu J; Gilbertson DT; Arneson TJ; Collins AJ
    Pharmacotherapy; 2009 Feb; 29(2):154-64. PubMed ID: 19170585
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Defining the role of sevelamer chloride as a therapeutic agent for management of phosphate in patient with hemodialysis].
    Hashimoto N; Miyata M; Sato N; Mochizuki T; Koike T
    Clin Calcium; 2005 Sep; 15 Suppl 1():30-4; discussion 34. PubMed ID: 16272626
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.